Enterprise capital fund Oncology Ventures introduced the shut of an oversubscribed $30 million Fund I to spend money on data-driven startups bettering most cancers care and analysis.
New York-based Oncology Ventures is led by Ben Freeberg, a healthcare investor who beforehand served as vice chairman at Optum Ventures and was the primary rent at Alpha Companions. Freeberg mentioned his operational expertise at most cancers startup Thyme Care and his private expertise as a most cancers survivor place him properly to spend money on and empower the following technology of most cancers startups.
“Most cancers care immediately is prohibitively costly and overly advanced. We are going to spend money on cutting-edge information and AI options to sort out essentially the most urgent challenges in oncology, from early detection to remedy optimization,” mentioned Freeberg, founder and managing associate of Oncology Ventures, in a press release. “We’re excited by the overwhelming help for our first fund to speed up most cancers innovation.”
Oncology Ventures’ advisory board incorporates a distinguished group of healthcare, enterprise and oncology specialists, together with the previous Chief Medical Officer of UnitedHealth Group (Dr. Lee Newcomer), the co-founder of Threshold Ventures (Emily Melton), CEO of Flatiron Well being (Carolyn Starrett) and CEO of OneOncology (Dr. Jeff Patton).
Moreover, the fund is backed by a number of establishments, together with Cardinal Well being, Metropolis of Hope, and Moffitt Most cancers Heart.
Oncology Ventures has made seven investments starting from early detection for most cancers (Gabbi and mPATH) to care navigation throughout remedy (Reimagine Care) by to survivorship care (OncoveryCare). The fund is also investing in corporations targeted on most cancers medical trials (IgniteData), precision oncology (Concr) and healthcare AI enablement ( Well being Univers).
